Venrock Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
25
- Investments
-
1,005
- Portfolio
-
116
- Exits
-
470
Venrock General Information
Description
Founded in 1969, Venrock is a Venture Capital arm of Rockefeller Group Investment Management based in Palo Alto, California. The firm has additional offices in Boston and New York. The firm seeks to invest in companies operating in the technology, healthcare, consumer, cryptocurrency, cybersecurity, defense & aerospace, security & infrastructure, financial technology, software-as-a-service, and artificial intelligence sectors based in the United States.
Contact Information
Investor Status
Actively Seeking New Investments
Trade Association
New England Venture Capital Association (NEVCA)
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- 3340 Hillview Avenue
- Silicon Valley
- Palo Alto, CA 94304
- United States
+1 (650) 000-0000
Venrock Investments & Acquisitions (1,005)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| MBrace Therapeutics | 21-Nov-2023 | Early Stage VC | 0000 | Drug Discovery | Pre-Clinical Trials | 0000000 0000000 |
| Viridian Therapeutics | 01-Nov-2023 | 0000 | 00000 | Biotechnology | Generating Revenue/Not Profitable | |
| Scope3 | 19-Sep-2023 | 00000 00000 | 0000 | Media and Information Services (B2B) | Generating Revenue | 0000000 0000000 |
| Dianthus Therapeutics | 11-Sep-2023 | 0000 | 0000 | Drug Discovery | Generating Revenue/Not Profitable | |
| Moment (Financial Software) | 06-Sep-2023 | 0000 00000 | 0000 | Financial Software | Generating Revenue | |
| Taysha Gene Therapies | 16-Aug-2023 | 0000 | 00000 | Drug Discovery | Generating Revenue/Not Profitable | |
| ADARx Pharmaceuticals | 02-Aug-2023 | 00000 00000 | 00000 | Biotechnology | Clinical Trials - Phase 1 | |
| Tisento Therapeutics | 01-Aug-2023 | 00000 00000 | 0000 | Biotechnology | Clinical Trials - Phase 2 | |
| Upstream Bio | 06-Jul-2023 | Early Stage VC | 00000 | Biotechnology | Clinical Trials - General | 0000 00000 00 |
| Candid (Therapeutic Devices) | 29-Jun-2023 | Later Stage VC | 000 | Therapeutic Devices | Generating Revenue |
Venrock Exits (470)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Sitka | 14-Nov-2023 | Merger/Acquisition | |
| RayzeBio | 15-Sep-2023 | 000 | 00000 |
| Dianthus Therapeutics | 11-Sep-2023 | 0000000 000000 | 00000 |
| Socrates.Ai | 15-Aug-2023 | 000000000000000000 | |
| Apogee Therapeutics | 13-Jul-2023 | 000 | 00000 |
| Lusaris Therapeutics | 30-May-2023 | 000 00 00000000 | |
| Qteros | 01-Mar-2023 | 000000000 00000000 | |
| Replicor | 01-Feb-2023 | 000000000 00000000 | |
| Burner | 01-Dec-2022 | Secondary Transaction - Private | |
| Market Realist | 01-Nov-2022 | Merger/Acquisition |
Venrock Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
Venrock Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
Venrock Team (87)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Lisa Harris | Chief Financial Officer & Finance Partner | Palo Alto, CA | |||
| Evan Neu | Partner, Chief Compliance Officer & General Counsel | Palo Alto, CA | |||
| Nicole Pack | Chief Marketing Officer & Marketing Partner | Palo Alto, CA | |||
| Brian Ascher | Partner | 00 | 0 | 0 | Palo Alto, CA |
| Camille Samuels | Partner | 00 | 00 | 0 | Palo Alto, CA |
Venrock Co-Investors (647)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Logos Capital | 14 | 0 | 0 |
|
|
| RA Capital Management | 00 | 0 | 00 |
|
|
| Fidelity Management & Research | 00 | 0 | 0 |
|
|
| Janus Henderson Investors | 00 | 0 | 0 |
|
|
| OrbiMed | 00 | 0 | 0 |
|
|